Angeles Wealth Management LLC Buys 182 Shares of Zoetis Inc. (NYSE:ZTS)

Angeles Wealth Management LLC raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 9.9% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,016 shares of the company’s stock after acquiring an additional 182 shares during the period. Angeles Wealth Management LLC’s holdings in Zoetis were worth $394,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Prevail Innovative Wealth Advisors LLC grew its position in shares of Zoetis by 24.5% during the 1st quarter. Prevail Innovative Wealth Advisors LLC now owns 18,977 shares of the company’s stock worth $3,211,000 after purchasing an additional 3,738 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its stake in Zoetis by 58.6% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 41,931 shares of the company’s stock worth $7,095,000 after acquiring an additional 15,491 shares during the period. Duality Advisers LP increased its stake in Zoetis by 43.7% during the 1st quarter. Duality Advisers LP now owns 40,641 shares of the company’s stock worth $6,877,000 after acquiring an additional 12,359 shares during the period. M&G Plc bought a new stake in shares of Zoetis during the 1st quarter valued at $19,819,000. Finally, Cetera Investment Advisers lifted its position in shares of Zoetis by 275.2% during the 1st quarter. Cetera Investment Advisers now owns 96,085 shares of the company’s stock valued at $16,259,000 after acquiring an additional 70,476 shares during the period. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $181.95 on Monday. The firm’s fifty day moving average price is $188.97 and its two-hundred day moving average price is $178.87. The stock has a market cap of $82.43 billion, a PE ratio of 35.61, a PEG ratio of 2.78 and a beta of 0.90. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The business had revenue of $2.36 billion during the quarter, compared to analysts’ expectations of $2.31 billion. During the same quarter in the prior year, the firm earned $1.41 EPS. The business’s revenue for the quarter was up 8.3% compared to the same quarter last year. On average, equities analysts expect that Zoetis Inc. will post 5.83 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a yield of 0.95%. Zoetis’s dividend payout ratio is presently 33.66%.

Wall Street Analyst Weigh In

A number of research firms recently commented on ZTS. JPMorgan Chase & Co. boosted their price target on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. BTIG Research increased their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Wednesday, August 14th. Finally, Stifel Nicolaus raised their target price on Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $221.44.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.